U.S. Life Sciences Stock News

NasdaqCM:ISPR
NasdaqCM:ISPRTobacco

Ispire Technology (ISPR) Loss Of US$6.6m In Q2 2026 Reinforces Bearish Narratives

Ispire Technology (NasdaqCM:ISPR) opened Q2 2026 with total revenue of about US$20.3 million and a basic EPS loss of US$0.12, alongside a net income loss of roughly US$6.6 million. This frames a clear focus on how efficiently that revenue is translating into earnings. The company has reported quarterly revenue between about US$20.1 million and US$41.8 million over the past six reported periods, while basic EPS has ranged from a loss of US$0.06 to a loss of US$0.26, giving investors a concrete...
NasdaqGS:RBBN
NasdaqGS:RBBNCommunications

Ribbon Communications (RBBN) Is Down 25.2% After Swinging To 2025 Profit And Cutting 2026 Outlook – Has The Bull Case Changed?

Ribbon Communications Inc. recently reported its Q4 and full-year 2025 results, with Q4 revenue of US$227.32 million and net income of US$89.07 million, alongside issuing 2026 revenue guidance of US$160 million to US$170 million for Q1 and US$840 million to US$875 million for the full year. An interesting shift in 2025 was the move from a full-year net loss of US$54.24 million to net income of US$39.64 million, highlighting a materially improved bottom line despite relatively stable annual...
NasdaqGS:FTNT
NasdaqGS:FTNTSoftware

Assessing Fortinet (FTNT) Valuation After Mixed Short And Long Term Shareholder Returns

Setting the scene on Fortinet after recent performance Fortinet (FTNT) has caught investor attention after a mixed stretch in returns, with a 6.3% gain year to date but a 23.1% decline over the past year. That context frames how you might view its current fundamentals. See our latest analysis for Fortinet. Recent trading has been choppy, with a 4.85% 1 day share price return and a 4.47% 30 day share price return at a last close of $82.76. The 1 year total shareholder return of 23.1% contrasts...
NasdaqGS:URBN
NasdaqGS:URBNSpecialty Retail

Did Strong Comp Sales and Buybacks Just Shift Urban Outfitters' (URBN) Investment Narrative?

In recent updates, Urban Outfitters highlighted that comparable store sales at its existing locations have risen by an average of 4.6% over the past two years, and its sales outlook for the next 12 months points to more momentum than many apparel peers. An additional insight is that share repurchases over the past three years have helped annual earnings per share growth of 41.8% outpace the company’s revenue expansion, underscoring how capital allocation choices can amplify shareholder...
NYSE:CTVA
NYSE:CTVAChemicals

How Investors Are Reacting To Corteva (CTVA) Spinning Off Seeds After Bayer Deal And Record Cash Flow

Corteva, Inc. reported its fourth-quarter and full-year 2025 results in early February, with quarterly sales easing to US$3,910 million and a net loss of US$552 million, but full-year sales rising to US$17.40 billion and net income reaching US$1.09 billion. Alongside record free cash flow of US$2.90 billion, Corteva resolved long-running seed-licensing litigation with Bayer and reaffirmed its plan to spin off the seeds business around late 2026, reshaping its future as a pure-play crop...
NasdaqGS:BIIB
NasdaqGS:BIIBBiotechs

Biogen (BIIB) Q4 Loss And Margin Compression Reinforce Bearish Profitability Narratives

Biogen FY 2025 earnings snapshot Biogen (BIIB) has wrapped up FY 2025 with Q4 revenue of US$2,279.4 million and a basic EPS loss of US$0.33, as the market weighs these numbers against already softening profitability. Over the past six quarters, revenue has moved from US$2,465.8 million in Q3 2024 to a peak of US$2,645.5 million in Q2 2025 before landing at US$2,279.4 million in Q4 2025. Quarterly EPS has ranged from US$2.67 in Q3 2024 up to US$4.33 in Q2 2025 before turning negative in the...
NasdaqGS:BCRX
NasdaqGS:BCRXBiotechs

Is Biocryst Pharmaceuticals (BCRX) Attractively Priced After Extended Share Price Weakness?

If you are trying to work out whether BioCryst Pharmaceuticals at around US$6.38 is priced attractively or not, it helps to first separate the recent share price moves from the underlying value story. The stock has been under pressure recently, with returns of a 3% decline over the last 7 days, a 13.8% decline over the last 30 days, a 14.9% decline year to date, and a 26.8% decline over the last year. The 3 year and 5 year returns sit at 38.1% and 33.3% declines respectively. Recent news...
NasdaqGS:LULU
NasdaqGS:LULULuxury

Founder Wilson Challenges Lululemon Board As Shares Lag Analyst Targets

Dennis J. Wilson, founder of lululemon athletica, plans to nominate his own board slate for the company’s 2026 annual meeting. Wilson also intends to introduce a business proposal, signaling a push to regain influence over the company’s direction and governance. The move will involve filing a proxy statement ahead of the meeting, giving current shareholders a direct say on potential board changes. For investors watching NasdaqGS:LULU, this comes at a time when the share price is $172.85 and...